VBC enablement, sold by reps who can talk risk economics.
Selling into a risk-bearing provider organization is a finance conversation as much as a clinical one. The buyer is evaluating program impact on PMPM, MLR, quality scores, and shared savings — Solara reps can hold that conversation.
Why VBC enablement is hard to sell
VBC programs aren't bought on features. They're bought on projected impact on a financial model — a model the buyer is already running. A rep who can't engage with that model loses to one who can. Solara reps are trained on the risk-economics conversation specific to the program category they cover.
What changes when value-based care runs on the Solara network.
Risk-economics fluency by program
Reps are trained on MSSP attribution, MA risk-adjustment, bundled-payment construction, kidney-care risk, and primary-care risk economics — depending on the manufacturer's program category.
Buyer is the CFO, CMO, or VP-VBC
These deals don't close in a clinical demo. Reps are calling on health-system VBC leadership, ACO executive teams, IPA finance, and risk-bearing primary-care groups. Different territory routing, different rep profile.
Program-impact analytics post-sale
Adoption isn't the conversion event — program impact is. We track per-account attributed-population metrics, PMPM movement, and quality-score change so the manufacturer can demonstrate impact at renewal.
Specialties served by this category.
- ·Health-system VBC leadership
- ·ACO executive and clinical teams
- ·IPA and CIN leadership
- ·Risk-bearing primary-care groups
- ·Specialty risk pods (kidney care, oncology, etc.)
Who Solara distributes for in this category.
- ·VBC enablement platforms (population-health, risk analytics, care-management workflow)
- ·ACO MSSP service organizations
- ·MA risk-adjustment and HCC capture tooling
- ·Bundled-payment management software
- ·Specialty risk programs (kidney care, oncology, etc.)
What manufacturers ask before they pilot.
- Who buys VBC enablement at the provider organization?
- VBC leadership, CMO, CFO, or a designated VP of population health or value-based care. Solara reps for this category are routed to those buyers, not to clinical operations or practice management.
- Can Solara reps engage with risk-economics modeling?
- Yes. Reps for VBC accounts are trained on the financial model behind the program category they cover — MSSP, MA, bundled, kidney care — and can engage with the buyer's projection at the level of attribution, PMPM, and shared-savings construction.
- How does Solara handle long sales cycles typical of VBC deals?
- VBC deals close on six- to eighteen-month cycles. The platform tracks pipeline at stage granularity, and rep compensation is structured to reward closed-won, not first-meeting volume.
- Does Solara sell into Medicaid managed-care or duals programs?
- Yes — Medicaid managed-care, D-SNP, and integrated dual-eligible programs are within scope where the manufacturer has a relevant offering. Routing follows the buyer profile, not the patient population.
Pilot a value-based care territory in 30 days.
Book a working session — we’ll load your target sub-segment into Solara live, walk through territory coverage, and propose a pilot scope.